Nothing Special   »   [go: up one dir, main page]

FR22C1033I1 - Utilisation de dihydroimidazolones pour le traitement des chiens - Google Patents

Utilisation de dihydroimidazolones pour le traitement des chiens

Info

Publication number
FR22C1033I1
FR22C1033I1 FR22C1033C FR22C1033C FR22C1033I1 FR 22C1033 I1 FR22C1033 I1 FR 22C1033I1 FR 22C1033 C FR22C1033 C FR 22C1033C FR 22C1033 C FR22C1033 C FR 22C1033C FR 22C1033 I1 FR22C1033 I1 FR 22C1033I1
Authority
FR
France
Prior art keywords
dihydroimidazolones
dogs
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1033C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of FR22C1033I1 publication Critical patent/FR22C1033I1/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1033C 2002-10-10 2022-06-30 Utilisation de dihydroimidazolones pour le traitement des chiens Active FR22C1033I1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
EP08167818A EP2036563A1 (fr) 2002-10-10 2003-10-09 Utilisation de dihydroimidazolones pour le traitement des troubles du comportement chez les chiens
EP03757945A EP1553952B1 (fr) 2002-10-10 2003-10-09 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
PCT/EP2003/011212 WO2004032938A1 (fr) 2002-10-10 2003-10-09 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine

Publications (1)

Publication Number Publication Date
FR22C1033I1 true FR22C1033I1 (fr) 2022-09-09

Family

ID=32094042

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0044C Active FR13C0044I2 (fr) 2002-10-10 2013-07-24 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR22C1033C Active FR22C1033I1 (fr) 2002-10-10 2022-06-30 Utilisation de dihydroimidazolones pour le traitement des chiens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR13C0044C Active FR13C0044I2 (fr) 2002-10-10 2013-07-24 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine

Country Status (28)

Country Link
US (5) US20050070537A1 (fr)
EP (3) EP1553952B1 (fr)
JP (4) JP4694202B2 (fr)
KR (2) KR101110587B1 (fr)
CN (2) CN1726040B (fr)
AR (1) AR041573A1 (fr)
AT (1) ATE418337T1 (fr)
AU (2) AU2003273978B2 (fr)
BE (1) BE2013C046I2 (fr)
BR (1) BR0315225A (fr)
CA (2) CA2727722C (fr)
CY (3) CY1109961T1 (fr)
DE (1) DE60325496D1 (fr)
DK (2) DK1553952T3 (fr)
ES (2) ES2908453T3 (fr)
FR (2) FR13C0044I2 (fr)
HK (1) HK1085920A1 (fr)
HR (3) HRP20090667B1 (fr)
HU (2) HUS1300035I1 (fr)
LU (1) LU92238I2 (fr)
MX (1) MXPA05003663A (fr)
NZ (1) NZ539864A (fr)
PL (2) PL238776B1 (fr)
PT (2) PT2845594T (fr)
SI (2) SI2845594T1 (fr)
TW (2) TWI324067B (fr)
WO (1) WO2004032938A1 (fr)
ZA (1) ZA200502245B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
UA87982C2 (ru) * 2003-07-11 2009-09-10 Берингер Ингельхайм Ветмедика Гмбх Способ лечения или предотвращения расстройств центральной нервной системы производными 1-ар(алк)-4-пиперидиноимидазолин-2-она, фармацевтическая композиция
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
CN106459030B (zh) 2014-05-28 2019-01-29 东亚荣养株式会社 取代托品烷衍生物
EP3193862B1 (fr) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Composition topique de cannabinoïdes pour le traitement de la douleur arthritique
WO2016118391A1 (fr) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Compositions et procédés de traitement de troubles épileptiques
WO2017027651A1 (fr) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Méthode et composition pour traiter la cachexie et les troubles de l'alimentation
CA3027862A1 (fr) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Methode et composition pour traiter des troubles epileptiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de) 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
EP0991614A1 (fr) * 1997-06-26 2000-04-12 Board of Regents, The University of Texas System Synthese de compositions de dihydrohonokiol
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
NZ535663A (en) 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
JP2016104817A (ja) 2016-06-09
BE2013C046I2 (fr) 2022-08-09
TW200503726A (en) 2005-02-01
SI1553952T1 (sl) 2009-04-30
CA2501772A1 (fr) 2004-04-22
FR13C0044I1 (fr) 2013-08-30
AU2009225322A1 (en) 2009-11-05
DK2845594T3 (da) 2022-03-07
HUS1300035I1 (hu) 2017-10-30
LU92238I9 (fr) 2019-01-09
PT1553952E (pt) 2009-02-10
BR0315225A (pt) 2005-08-23
CY1125103T1 (el) 2023-01-05
KR20110063843A (ko) 2011-06-14
JP2006503873A (ja) 2006-02-02
HRP20200207A2 (hr) 2020-07-24
HRP20090667A2 (hr) 2010-07-31
ES2908453T3 (es) 2022-04-29
PL374603A1 (en) 2005-10-31
CN101890019A (zh) 2010-11-24
WO2004032938A1 (fr) 2004-04-22
ZA200502245B (en) 2005-11-30
NZ539864A (en) 2007-11-30
PL397320A1 (pl) 2012-02-13
JP2011068685A (ja) 2011-04-07
US20150072983A1 (en) 2015-03-12
PL238776B1 (pl) 2021-10-04
HRP20050322B1 (hr) 2013-12-06
US8859540B2 (en) 2014-10-14
US9469611B2 (en) 2016-10-18
CA2727722C (fr) 2013-05-28
ATE418337T1 (de) 2009-01-15
EP2845594A1 (fr) 2015-03-11
ES2316808T3 (es) 2009-04-16
HRP20050322A2 (en) 2006-05-31
HRP20090667B1 (hr) 2021-06-11
PL214702B1 (pl) 2013-09-30
SI2845594T1 (sl) 2022-04-29
AU2003273978A1 (en) 2004-05-04
TWI324067B (en) 2010-05-01
MXPA05003663A (es) 2005-06-08
CA2501772C (fr) 2011-08-23
EP2845594B1 (fr) 2022-02-23
HK1085920A1 (en) 2006-09-08
US8962617B2 (en) 2015-02-24
TWI424849B (zh) 2014-02-01
PT2845594T (pt) 2022-03-09
DK1553952T3 (da) 2009-04-20
JP6249812B2 (ja) 2017-12-20
EP2036563A1 (fr) 2009-03-18
KR101110587B1 (ko) 2012-02-15
EP1553952B1 (fr) 2008-12-24
CY1109961T1 (el) 2014-09-10
AU2003273978B2 (en) 2009-07-23
LU92238I2 (fr) 2013-09-03
TW201010706A (en) 2010-03-16
CN1726040A (zh) 2006-01-25
US20050070537A1 (en) 2005-03-31
EP1553952A1 (fr) 2005-07-20
JP4694202B2 (ja) 2011-06-08
AR041573A1 (es) 2005-05-18
KR20050056237A (ko) 2005-06-14
CA2727722A1 (fr) 2004-04-22
US20130065898A1 (en) 2013-03-14
JP2014080449A (ja) 2014-05-08
DE60325496D1 (de) 2009-02-05
CY2013031I1 (el) 2015-11-04
CY2013031I2 (el) 2015-11-04
CN1726040B (zh) 2010-05-12
US20080027057A1 (en) 2008-01-31
US20160367562A1 (en) 2016-12-22
HUS2200036I1 (hu) 2022-08-28
FR13C0044I2 (fr) 2014-03-07

Similar Documents

Publication Publication Date Title
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
NO20021526D0 (no) Anordning for kloakkbehandling
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
MA27395A1 (fr) Utilisation de prebiotiques pour le traitement et la prevention des syndromes hyper-glycemiques
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
SE0301854L (sv) Antiigensättningsbehandling
FR2868307B1 (fr) Utilisation de beta-endorphine pour le traitement des rides
FR2868312B1 (fr) Patch pour le traitement des levres
FR2834887B1 (fr) Utilisation d'un extrait d'artemia pour le traitement des peaux agees
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2832429B1 (fr) Dispositif porte-pieces perfectionne pour traitement electrolytique
FR2843015B1 (fr) Implant pour le traitement de la presbytie
FR2844197B1 (fr) Solution pour application ungueale et peri-ungeale
FR2825893B3 (fr) Tunnel de traitement
IT1316554B1 (it) Dispositivo per il trattamento di rifiuti umidi.
NO20033160D0 (no) Anordning for behandling av gravann
FR2839851B1 (fr) Dispositif pour le traitement des arbres
FR2887456B1 (fr) "composition pour le traitement de la dermite estivale"
FR2855400B1 (fr) Dispositif rectal, notamment pour le traitement des hemorrhoides
FR2820025B1 (fr) Dispositif pour le traitement de la presbytie
MA26147A1 (fr) Equipement pour le traitement de finissage des metaux.
FR2818910B1 (fr) Appareil pour le traitement de la peau
FR2879450B1 (fr) Antagonistes des recepteurs peripheriques des benzodiazepines pour le traitement des peaux seches